Skip to main content

Visipaque Dosage

Generic name: IODIXANOL 320mg in 1mL
Dosage form: injection
Drug class: Non-ionic iodinated contrast media

Medically reviewed by Drugs.com. Last updated on Mar 1, 2024.

Important Dosage and Administration Instructions

  • VISIPAQUE is for intravascular use only
  • Use sterile technique for all handling and administration of VISIPAQUE.
  • Do not use if tamper-evident ring is broken or missing.
  • Warm VISIPAQUE and administer at body or room temperature.
  • Inspect VISIPAQUE for particulate matter or discoloration before administration, whenever solution and container permit. Do not administer if VISIPAQUE contains particulate matter or is discolored.
  • Do not mix VISIPAQUE with, or inject in intravenous lines containing, other drugs or total nutritional admixtures.
  • Use the lowest dose necessary to obtain adequate visualization.
  • Individualize the volume, strength, and rate of administration of VISIPAQUE. Consider factors such as age, bodyweight, vessel size, blood flow rate within the vessel, anticipated pathology, degree and extent of opacification required, structures or area to be examined, disease processes affecting the patient, and equipment and technique to be employed.
  • The maximum recommended total dose of iodine for adults is 80 grams.
  • Avoid extravasation when injecting VISIPAQUE; especially in patients with severe arterial or venous disease.
  • Hydrate patients before and after VISIPAQUE administration .

Intra-Arterial Dosage and Administration

  • Intra-arterial digital subtraction angiography(IA-DSA) (270 and 320 mg Iodine/mL)
  • Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography(320 mg Iodine/mL)

Use Injection rates approximately equal to the flow rate in the vessel being injected. The usual single injection volumes or total dose per patient (mL/kg) for adults and adolescents over 12 years of age are listed in Table 1.

TABLE 1
ADULTS and PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER VISIPAQUE SINGLE DOSE RECOMMENDATIONS FOR INJECTION INTO SELECTED ARTERIES
ARTERIOGRAPHY IA-DSA * Maximum Total Dose
Intra-Arterial Injection Sites 320 mg Iodine/mL 270 mg Iodine/mL 320 mg Iodine/mL
*
IA-DSA = Intra-Arterial Digital Subtraction Angiography
Carotid Arteries 10 to 14 mL 5 to 8 mL Usually Not to Exceed 175 mL
Vertebral Arteries 10 to 12 mL 5 to 8 mL
Right Coronary Artery 3 to 8 mL Usually Not to Exceed 200 mL
Left Coronary Artery 3 to 10 mL
Left Ventricle 20 to 45 mL
Renal Arteries 8 to 18 mL 10 to 25 mL -- Usually Not to Exceed 250 mL
Aortography 30 to 70 mL 20 to 50 mL 10 to 50 mL
Major Branches of Aorta 10 to 70 mL 5 to 30 mL 2 to 10 mL
Aortofemoral Runoffs 20 to 90 mL -- 6 to 15 mL
Peripheral Arteries 15 to 30 mL -- 3 to 15 mL

Intravenous Dosage and Administration

  • Computed Tomography of the Head or Body (270 mg Iodine/mL and 320 mg Iodine/mL)
  • Excretory Urography (270 mg Iodine/mL and 320 mg Iodine/mL)
  • Peripheral Venography (270 mg Iodine/mL)
  • Coronary Computed Tomography Angiography (CCTA) (320 mg Iodine/mL)

Recommended dosage of VISIPAQUE is dependent on: the administration procedure, patient weight, and CT device factors, as detailed in Table 2. Calibrate the intravenous injection rate so that image acquisition coincides with peak arterial concentration. The time between VISIPAQUE injection and peak arterial concentration varies between patients. Selected dosing for different indications in adults and pediatric patients over 12 years of age are shown in Table 2.

TABLE 2
ADULTS and PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER VISIPAQUE DOSING RECOMMENDATIONS FOR INTRAVENOUS CONTRAST ADMINISTRATION
Study Type Comment 270 mg Iodine/mL 320 mg Iodine/mL Maximum Total Volume
*
2 For pediatric patients aged 12 to 17, recommended dose is 1 to 2 mL/kg.
†
The main VISIPAQUE volume may be preceded by a test bolus consisting of 20 mL VISIPAQUE, immediately followed by a 20 mL saline flush, both injected at rate of 4 to 7 mL/sec.
‡
Injection of VISIPAQUE with saline can be either biphasic (without dilution phase) or triphasic (with dilution phase). Alternatively, a dose of 1 mL/kg may be used to calculate total VISIPAQUE dose (excluding any test bolus). For CCTA acquired at < 120 kVp, the dose of VISIPAQUE may be reduced by up to 15% in patients < 85 kg and BMI < 30 kg/m 2. For CCTA acquired on a scanner with more than 64 detector rows, the dose of VISIPAQUE may be reduced in proportion to the scan duration.
CT of Head or Body 1 Bolus 75 to 150 mL 75 to 150 mL 150 mL
Infusion 100 to 150 mL 100 to 150 mL
Excretory Urography Normal Renal Function 1 mL/kg 1 mL/kg 100 mL
Venography Per lower extremity 50 to 150 mL 250 mL
CCTA 1,2* Bolus injection with test bolus †or bolus tracking 50 to 150 mL ‡

(4 to 7 mL per second)		 150 mL

Dosage in Pediatric Patients Less Than 12 Years of Age

Intra-arterial Dosage and Administration

Angiocardiography, cerebral arteriography, or visceral arteriography(320 mg Iodine/mL) :

The recommended dosage is 1 to 2 mL/kg. The maximum dose should not exceed 4 mL/kg.

Intravenous Dosage and Administration

Computerized Tomography or Excretory Urography(270 mg Iodine/mL) :

The recommended dosage is 1 to 2 mL/kg. The maximum dose should not exceed 2 mL/kg.

Instructions for Use with an Automated Contrast Injection System or Contrast Management System for CT of the Head and Body

  • See above Important Dosage and Administration Instructions for VISIPAQUE ( 2.1).
  • See device labeling for information on device indications, instructions for use, and techniques to help assure safe use.
  • VISIPAQUE 320 mg Iodine/mL in 100 mL and 150 mL bottles may be used with a contrast media management system cleared for use with VISIPAQUE 320 in 100 mL and 150 mL bottles.
  • See device labeling for information on device indications, instructions for use, and techniques to help assure safe use.
  • Use sterile technique for penetrating the container closure of VISIPAQUE 320 and transferring VISIPAQUE solution.
  • Clean the stopper with a pad soaked in sporicidal solution followed by a pad soaked in alcohol, then puncture the stopper. The container closure may be penetrated only one time with a suitable sterile component of the contrast media management system cleared for use with VISIPAQUE 320 in 100 mL and 150 mL bottles.
  • Once the VISIPAQUE 320 Injection is punctured do not remove the bottle from the work area during the entire period of use.
  • Maximum use time is 4 hours after initial puncture.
  • Each bottle is for one procedure only. Discard unused portion.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer